The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Authors
Keywords
hypothyroidism, hyperthyroidism, thyroiditis, hypopituitarism, diabetes insipidus, adrenalitis, adrenal insufficiency, hypocalcemia, hypoparathyroidism, diabetes mellitus
Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 33, Issue 2, Pages 87-104
Publisher
Elsevier BV
Online
2021-12-09
DOI
10.1016/j.tem.2021.10.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy
- (2021) C. Luongo et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Endocrine toxicity of cancer immunotherapy: clinical challenges
- (2021) Bliss Anderson et al. Endocrine Connections
- How we treat endocrine complications of immune checkpoint inhibitors
- (2021) S.A. Paschou et al. ESMO Open
- Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome
- (2021) Keitaro Kanie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Endocrine complications of immunotherapies: a review
- (2021) Rosie Hattersley et al. CLINICAL MEDICINE
- Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review
- (2021) Pedro Iglesias et al. Pituitary
- Checkpoint blockade toxicities: Insights into autoimmunity and treatment
- (2021) Michael J. Walsh et al. SEMINARS IN IMMUNOLOGY
- Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice
- (2021) Sabrina Chiloiro et al. Journal of Personalized Medicine
- Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
- (2020) Chiaki Kurimoto et al. CANCER SCIENCE
- Time to dissect the autoimmune etiology of cancer antibody immunotherapy
- (2020) Michael Dougan et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma
- (2020) Kapil Agarwal et al. CLINICAL MEDICINE
- Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies
- (2020) Capucine Baldini et al. EUROPEAN JOURNAL OF CANCER
- Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency
- (2020) Seiichi Yano et al. EUROPEAN JOURNAL OF CANCER
- Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
- (2020) Virginie Grouthier et al. ONCOLOGIST
- PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
- (2020) Yasumasa Ishida Cells
- Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
- (2020) Angelos Kyriacou et al. CLINICAL MEDICINE
- Immune Checkpoint Inhibitor-Induced Thyroid Dysfunction is Associated with Higher Body Mass Index
- (2020) Rena Pollack et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
- (2020) Tomoko Kobayashi et al. Journal for ImmunoTherapy of Cancer
- Impact of age on the toxicity of immune checkpoint inhibition
- (2020) Amit Samani et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
- (2020) Daniele Marinelli et al. Cancers
- Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report
- (2019) Ayumu Takeno et al. BMC Endocrine Disorders
- A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2019) Jeroen de Filette et al. HORMONE AND METABOLIC RESEARCH
- Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients
- (2019) Pauline Campredon et al. PRESSE MEDICALE
- Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors
- (2019) I. Mazarico et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
- (2019) Elena Verzoni et al. Journal for ImmunoTherapy of Cancer
- The Changing Clinical Spectrum of Hypophysitis
- (2019) Sabrina Chiloiro et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis
- (2019) Hang Xu et al. Drug Design Development and Therapy
- Cancer immunotherapy-associated hypophysitis
- (2019) Franklin Castillero et al. Future Oncology
- Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
- (2019) Eva Kassi et al. Cancer Medicine
- Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study
- (2019) E. M. Presotto et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toxicities associated with checkpoint inhibitors—an overview
- (2019) Laura Spiers et al. RHEUMATOLOGY
- Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
- (2019) Jingli Lu et al. Cancer Medicine
- Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors
- (2019) Ruth Percik et al. AUTOIMMUNITY REVIEWS
- New insight in endocrine-related adverse events associated to immune checkpoint blockade
- (2019) Giusy Elia et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Diabetes associated with immune checkpoint inhibition: presentation and management challenges
- (2018) A Galligan et al. DIABETIC MEDICINE
- CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab
- (2018) Paola Queirolo et al. EUROPEAN JOURNAL OF CANCER
- MANAGEMENT OF ENDOCRINE DISEASE: Hypophysitis - diagnosis and treatment
- (2018) Mamta N Joshi et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review
- (2018) Katrien Clotman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
- (2018) Sandhya Manohar et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report
- (2018) Hitomi Umeguchi et al. Journal of Oncology Practice
- Expert opinion on immunotherapy induced diabetes
- (2018) Sarra Smati et al. ANNALES D ENDOCRINOLOGIE
- Association of anti-thyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
- (2018) Shiro Kimbara et al. CANCER SCIENCE
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- ImmuneCheckpoint Inhibitor-Induced Hypoparathyroidism Associated with Calcium-Sensing Receptor-Activating Autoantibodies
- (2018) Paramarajan Piranavan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Thyroid disorders induced by checkpoint inhibitors
- (2018) Silvia Martina Ferrari et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
- (2018) Priyanka C. Iyer et al. THYROID
- Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
- (2018) Lucien Marchand et al. ACTA DIABETOLOGICA
- Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)
- (2018) R. M. Ruggeri et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Comprehensive screening for PD-L1 expression in thyroid cancer
- (2017) Soomin Ahn et al. ENDOCRINE-RELATED CANCER
- DIAGNOSIS OF ENDOCRINE DISEASE: Primary empty sella: a comprehensive review
- (2017) S Chiloiro et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Current and future immunotherapies for thyroid cancer
- (2017) Alessandro Antonelli et al. Expert Review of Anticancer Therapy
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
- (2016) Patrizio Caturegli et al. AMERICAN JOURNAL OF PATHOLOGY
- Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
- (2016) M.N Joshi et al. CLINICAL ENDOCRINOLOGY
- Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient
- (2016) Yukiko Teramoto et al. JOURNAL OF DERMATOLOGY
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
- (2016) Elisa González-Rodríguez et al. ONCOLOGIST
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
- (2016) Subrata Chowdhury et al. Oncotarget
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Ipilimumab-Induced Adrenalitis
- (2015) Sara Bacanovic et al. CLINICAL NUCLEAR MEDICINE
- Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series
- (2015) T. Lam et al. INTERNAL MEDICINE JOURNAL
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma
- (2015) Shannon K. Quirk et al. Translational Research
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis
- (2014) Yosef Chodakiewitz et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autoimmune Thyroid Disease Elicited by NY-ESO-1 Vaccination
- (2013) Roberto Vita et al. THYROID
- IgG4-related hypophysitis presenting as a pituitary adenoma with systemic disease
- (2012) Ming-Tai Hsing et al. Asian Journal of Surgery
- MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
- (2012) A. Juszczak et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
- Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients.
- (2008) Mina Hayashi et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started